Olema Oncology Reports Preclinical Antitumour Activity of KAT6A Degraders in Breast Cancer Models

Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commerciali...

November 19, 2026 | Thursday | News
Erasca and Bristol Myers Squibb Partner to Test ERAS-0015 Combination in Pancreatic Cancer

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...

November 19, 2026 | Thursday | News
Cancer Research UK and Dewpoint Therapeutics Partner to Advance MYC-Targeting Cancer Drug into Phase 1/2a Trial

DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undrugg...

November 18, 2026 | Wednesday | News
Fortvita Biologics Receives Positive EMA CHMP Opinion for Zybrivo in First-Line Lung Cancer Treatment

Fortvita Biologics (Fortvita), a member of the Innovent Group (Innovent Biologics, Inc., HKEX Stock Code: 01801), announced that it has received its first ...

November 17, 2026 | Tuesday | News
Oncolytics Biotech and Coherus Partner to Evaluate Pelareorep and LOQTORZI Combination for Anal Cancer

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pela...

November 13, 2026 | Friday | News
OncoRes Medical Rebrands as Ziva Surgical to Advance Real-Time Cancer Detection During Surgery

OncoRes Medical announced its evolution to Ziva Surgical, unveiling a new name and visual identity as the Australian tissue intelligence company enters a d...

November 13, 2026 | Friday | News
Immutep Secures Fifth US Patent for Eftilagimod Alfa Combination Cancer Immunotherapy

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, an...

November 12, 2026 | Thursday | News
Elypta Study Finds Urine-Based GAGome Test Could Help Predict Five-Year Cancer Risk in Healthy Adults

A urine profile of three glycosaminoglycan disacharrides (GAGs) predicted five-year cancer risk in healthy adults, according to a peer-reviewed study publi...

November 12, 2026 | Thursday | News
SOTERIA’s CANCER HUNT Programme Expands Free Precision Cancer Care for US Veterans and Military Personnel

For military personnel and veterans diagnosed with cancer, accessing specialised testing and treatment options can be difficult, particularly when care...

November 09, 2026 | Monday | Interview
ArrayPatch Raises €3.2 Million in Seed Funding to Advance Microneedle Patch Treatments for Obesity and Cancer

ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, announced the successful completion of t...

November 06, 2026 | Friday | News
Agenus Reports 36% Major Pathologic Response in Phase 2 UNICORN Trial of Botensilimab and Balstilimab for Colon Cancer

In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, including 29% pathologic ...

November 04, 2026 | Wednesday | News
HUTCHMED and AstraZeneca Secure Regulatory Review in Europe and Japan for ORPATHYS and TAGRISSO Lung Cancer Combination

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) announces that regulatory filings for ORPATHYS® (savolitinib) in combinati...

November 03, 2026 | Tuesday | News
SOTERIA Launches Cancer Hunt Programme to Provide Free Precision Oncology Support for US Military Personnel and Veterans

SOTERIA Precision Medicine Foundation (SOTERIA), a California-based 501(c)(3) nonprofit, announces Cancer Hunt™, a nationwide precision oncology prog...

November 02, 2026 | Monday | News
Junshi Biosciences Secures China NMPA Acceptance for Subcutaneous Toripalimab in HER2-Expressing Urothelial Cancer

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

October 30, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close